BioAtla (BCAB) News Today $1.56 -0.15 (-8.77%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period FY2024 Earnings Forecast for BioAtla Issued By HC WainwrightBioAtla, Inc. (NASDAQ:BCAB - Free Report) - Investment analysts at HC Wainwright issued their FY2024 earnings estimates for BioAtla in a research report issued on Wednesday, November 13th. HC Wainwright analyst A. He expects that the company will post earnings per share of ($1.46) for the year. HNovember 15 at 7:35 AM | marketbeat.comMichael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 tradesNovember 14 at 3:27 PM | msn.comBioAtla: Strong Financials and Promising Clinical Progress Drive Buy RatingNovember 14 at 1:50 AM | markets.businessinsider.comHC Wainwright & Co. Downgrades BioAtla (BCAB)November 14 at 1:50 AM | msn.comBioAtla (BCAB) was downgraded to a Hold Rating at H.C. WainwrightNovember 14 at 1:50 AM | markets.businessinsider.comHC Wainwright Downgrades BioAtla (NASDAQ:BCAB) to NeutralHC Wainwright lowered shares of BioAtla from a "buy" rating to a "neutral" rating in a research report on Wednesday.November 13, 2024 | marketbeat.comBioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | msn.comBioAtla Reports Q3 2024 Financial Results and Clinical AdvancesNovember 9, 2024 | markets.businessinsider.comBioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ChallengesNovember 9, 2024 | finance.yahoo.comBioAtla, Inc. (BCAB) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comAlector (NASDAQ:ALEC) and BioAtla (NASDAQ:BCAB) Critical ComparisonNovember 9, 2024 | americanbankingnews.comBioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent ProgressNovember 7, 2024 | markets.businessinsider.comBioAtla (BCAB) to Release Quarterly Earnings on ThursdayBioAtla (NASDAQ:BCAB) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comBioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stakeOctober 31, 2024 | finance.yahoo.comBioAtla, Inc. (NASDAQ:BCAB) Sees Large Increase in Short InterestBioAtla, Inc. (NASDAQ:BCAB - Get Free Report) was the target of a large growth in short interest during the month of October. As of October 15th, there was short interest totalling 5,240,000 shares, a growth of 17.2% from the September 30th total of 4,470,000 shares. Based on an average daily volume of 1,180,000 shares, the short-interest ratio is currently 4.4 days.October 28, 2024 | marketbeat.comBioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025October 20, 2024 | msn.com636,136 Shares in BioAtla, Inc. (NASDAQ:BCAB) Acquired by AQR Capital Management LLCAQR Capital Management LLC acquired a new stake in BioAtla, Inc. (NASDAQ:BCAB - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 636,136 shares of the company's stock, valued at approximatelOctober 13, 2024 | marketbeat.comBioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial ChallengesOctober 10, 2024 | finance.yahoo.comBioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative BuyOctober 8, 2024 | seekingalpha.comRenaissance Technologies LLC Decreases Stock Holdings in BioAtla, Inc. (NASDAQ:BCAB)Renaissance Technologies LLC trimmed its holdings in shares of BioAtla, Inc. (NASDAQ:BCAB - Free Report) by 37.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 625,500 shares of the company's stock after selling 370,800 shOctober 8, 2024 | marketbeat.comBioAtla: Numerous Catalysts Coming In Q4October 7, 2024 | seekingalpha.comBioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual MeetingOctober 4, 2024 | globenewswire.comBioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International CongressOctober 1, 2024 | markets.businessinsider.comBioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International CongressOctober 1, 2024 | globenewswire.comMichael Burry just bought 633,959 shares in this $1 penny stockSeptember 30, 2024 | msn.comScion Asset Management LLC Purchases Shares of 633,959 BioAtla, Inc. (NASDAQ:BCAB)Scion Asset Management LLC purchased a new stake in BioAtla, Inc. (NASDAQ:BCAB - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 633,959 shares of the company's stock, valued at approximately $869,00September 27, 2024 | marketbeat.comBuy Rating Affirmed for BioAtla Amidst Strategic Collaborations and Promising Clinical CatalystsSeptember 24, 2024 | markets.businessinsider.comBioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging AntibodySeptember 23, 2024 | globenewswire.comBioAtla, Inc. (NASDAQ:BCAB) Sees Large Drop in Short InterestBioAtla, Inc. (NASDAQ:BCAB - Get Free Report) was the recipient of a large decline in short interest during the month of August. As of August 31st, there was short interest totalling 4,450,000 shares, a decline of 6.3% from the August 15th total of 4,750,000 shares. Based on an average daily trading volume, of 894,700 shares, the short-interest ratio is presently 5.0 days.September 18, 2024 | marketbeat.comBioAtla (NASDAQ:BCAB) Receives Market Outperform Rating from JMP SecuritiesJMP Securities reissued a "market outperform" rating and set a $5.00 target price on shares of BioAtla in a research note on Monday.September 16, 2024 | marketbeat.comBuy Rating Affirmed for BioAtla on Strong Clinical Data and Solid Financial PositioningSeptember 16, 2024 | markets.businessinsider.comBioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual MeetingSeptember 10, 2024 | markets.businessinsider.comCompanies Like BioAtla (NASDAQ:BCAB) Could Be Quite RiskySeptember 4, 2024 | finance.yahoo.comShort Interest in BioAtla, Inc. (NASDAQ:BCAB) Rises By 18.8%BioAtla, Inc. (NASDAQ:BCAB - Get Free Report) saw a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 4,750,000 shares, a growth of 18.8% from the July 31st total of 4,000,000 shares. Based on an average daily volume of 955,100 shares, the days-to-cover ratio is currently 5.0 days.August 31, 2024 | marketbeat.comBioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 28, 2024 | finance.yahoo.comBuy Rating for BioAtla: Promising Pipeline and Strategic Partnerships Fuel Optimistic OutlookAugust 21, 2024 | markets.businessinsider.comMichael Burry increases Alibaba stake, halves stock portfolioAugust 15, 2024 | msn.comMichael Burry of ‘The Big Short' increases Alibaba stake, halves stock portfolioAugust 15, 2024 | msn.comReni Benjamin’s Buy Rating for BioAtla: Strong Pipeline and Financial Health Signal Upside PotentialAugust 13, 2024 | markets.businessinsider.comBioAtla, Inc. (BCAB) Q2 2024 Earnings Call TranscriptAugust 11, 2024 | seekingalpha.comBioAtla (NASDAQ:BCAB) Issues Earnings Results, Beats Expectations By $0.01 EPSBioAtla (NASDAQ:BCAB - Get Free Report) released its earnings results on Thursday. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.01. During the same quarter last year, the company posted ($0.75) EPS.August 10, 2024 | marketbeat.comBioatla Reports Second Quarter 2024 Financial Results and Highlights Recent ProgressAugust 9, 2024 | markets.businessinsider.comBCAB Stock Earnings: BioAtla Meets EPS for Q2 2024August 9, 2024 | msn.comBioAtla, Inc. (BCAB) stock price, news, quote & history – Yahoo FinanceAugust 7, 2024 | sg.finance.yahoo.comBioAtla (BCAB) Set to Announce Quarterly Earnings on ThursdayBioAtla (NASDAQ:BCAB) will be releasing earnings after the market closes on Thursday, August 8, Zacks reports.August 2, 2024 | marketbeat.comBioAtla (BCAB) Receives a Buy from J.P. MorganJuly 29, 2024 | markets.businessinsider.comBioAtla, Inc. (NASDAQ:BCAB) Short Interest Down 24.2% in JulyBioAtla, Inc. (NASDAQ:BCAB - Get Free Report) was the target of a significant drop in short interest in the month of July. As of July 15th, there was short interest totalling 3,980,000 shares, a drop of 24.2% from the June 30th total of 5,250,000 shares. Based on an average daily volume of 880,600 shares, the short-interest ratio is currently 4.5 days.July 27, 2024 | marketbeat.comBioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D DayJuly 25, 2024 | globenewswire.comBioAtla Says Its Drug Ozuriftamab Vedotin To Treat SCCHN Got Fast Track DesignationJuly 23, 2024 | markets.businessinsider.com3 Penny Stocks With 735% Average Upside, According to Wall StreetJuly 9, 2024 | 247wallst.com Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Let’s be blunt (Ad)Let me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now BCAB Media Mentions By Week BCAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCAB News Sentiment▼0.530.56▲Average Medical News Sentiment BCAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCAB Articles This Week▼132▲BCAB Articles Average Week Get BioAtla News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CGC News VYGR News SAGE News CYRX News TKNO News QURE News LYEL News CMPS News JSPR News STRO News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCAB) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioAtla With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCAB Stock Alerts